23th June, 2022 – Trinomab issued a press release, which is summarized as follows:
On June 15, 2022, the high-profile 2022 Future Healthcare VB100 List was released on the 6th Top 100 Future Medical Cloud Summit. Trinomab was selected for the “2022 Future Healthcare VB100 – Top 100 Innovative Biomedicine Companies”.
The 2022 Future Healthcare VB100 is the first domestic non-listed company ranking in the medical innovation field jointly launched by VB100, VBData and VCBeat Research. As an annual selection in the life science field that attracts the most attention from the industry and capital market, it aims to select Chinese innovative companies that truly represent the future of health care, and to discover the core strength of China’s future health care industry. The selection of China’s Top 100 Innovative Biomedicine Companies in 2022 ranks the top 100 non-listed innovative biomedicine companies in valuation based on their growth and annual performance in human resources, knowledge resources, important partners, market performance, etc.
As an innovative biomedical company focusing on R&D and industrialization of natural fully human monoclonal antibody drugs, Trinomab, with its comprehensive strength and significant growth advantages in core technologies, product R&D capabilities, pipeline progresses and future market prospects, has been favored and recognized by many leading investment companies, including Hillhouse Capital, CMB International, CICC Capital, and Riverhead Capital Investment. By December 2021, it has completed nearly RMB1.3 billion equity financing. Trinomab’s self-developed fully human anti-tetanus mAb and fully human RSV mAb have entered the clinical stage, among which, the fully human anti-tetanus mAb TNM002 injection was granted the breakthrough therapy designation by CDE in March this year, and it is so far the only fully human mAb against tetanus that has entered the clinical stage globally.
Original website Link: